Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification
Michael T. Parsons, Emma Tudini, Hongyan Li et al. · Human Mutation · 2019
The multifactorial likelihood analysis method has demonstrated utility for quantitative assessment of variant pathogenicity for multiple cancer syndrome genes. Independent data types currently incorporated in the model for assessing BRCA1 and BRCA2 variants include clinically calibrated prior probability of pathogenicity based on variant location and bioinformatic prediction of variant effect, co-segregation, family cancer history profile, co-occurrence with a pathogenic variant in the same gene, breast tumor pathology, and case-control information. Research and clinical data for multifactorial likelihood analysis were collated for 1,395 BRCA1/2 predominantly intronic and missense variants, enabling classification based on posterior probability of pathogenicity for 734 variants: 447 variants were classified as (likely) benign, and 94 as (likely) pathogenic; and 248 classifications were new or considerably altered relative to ClinVar submissions. Classifications were compared with information not yet included in the likelihood model, and evidence strengths aligned to those recommended for ACMG/AMP classification codes. Altered mRNA splicing or function relative to known nonpathogenic variant controls were moderately to strongly predictive of variant pathogenicity. Variant absence in population datasets provided supporting evidence for variant pathogenicity. These findings have direct relevance for BRCA1 and BRCA2 variant evaluation, and justify the need for gene-specific calibration of evidence types used for variant classification.
Cited by 145 works. doi:10.1002/humu.23818 Open-access PDF
Authors
- Michael T. Parsons
- Emma Tudini
- Hongyan Li
- Eric Hahnen
- Barbara Wappenschmidt
- Lídia Feliubadaló
- Cora M. Aalfs
- Simona Agata
- Kristiina Aittomäki
- Elisa Alducci
- María Concepción Alonso‐Cerezo
- Norbert Arnold
- Bernd Auber
- Rachel Austin
- Jacopo Azzollini
- Judith Balmañà
- Elena Barbieri
- Claus Rainer Bartram
- Ana Blanco
- Britta Blümcke
References
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
- Risks of cancer in BRCA1-mutation carriers
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
- Cancer Risks in BRCA2 Mutation Carriers
- ClinGen — The Clinical Genome Resource
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
- Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results
- Integrated Evaluation of DNA Sequence Variants of Unknown Clinical Significance: Application to BRCA1 and BRCA2
- Cancer Incidence in BRCA1 Mutation Carriers
- Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database